Skip to main content
Equibles
URGN logo

URGN · UroGen Pharma Ltd. · Metrics

Track URGN — free

Use URGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research URGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.91 -0.13 (-0.38%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.65B
Shares
48.88M
Volume · Oct 27 1.03M Avg daily vol (3M) 904.32K

URGN metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$33.91
Market cap
$1.65B

Price action

20 metrics
Price change (1W)
-0.3%
Price change (30D)
-16.8%
Price change (3M)
-17.9%
Price change (6M)
+43.2%
Price change (YTD)
+45.3%
Price change (1Y)
+79.4%
Trailing year
Price change (5Y)
+106.8%
52-week high
$50.29
52-week low
$17.00
Change from 52-week high
-32.3%
Change from 52-week low
+100.2%
Annualized volatility
62.8%
Annualized volatility (3M)
54.2%
Beta
1.2
RSI (14D)
30.3
Price vs SMA 50
-18.3%
Price vs SMA 200
+9.7%
Avg volume (3M)
896,381
Relative volume
0.8
Average dollar volume
$37.87M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.88M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
9.3×
reciprocal yield 10.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.9×
reciprocal yield 11.3%
P / book
—
FCF yield
-9.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
90.8%
Operating margin
-35.3%
Trailing 12 months
Net margin
-51.7%
Gross profit (TTM)
$171.46M
Operating profit (TTM)
−$66.65M
Net income (TTM)
−$97.64M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-84.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.15
Gross profit per diluted share (TTM)
$1.92
Operating profit per diluted share (TTM)
$-4.13
EBITDA per diluted share (TTM)
$-4.09
Net income per diluted share (TTM)
$-4.96
Operating cash flow per diluted share (TTM)
$-3.80
Free cash flow per diluted share (TTM)
$-3.83
Capital expenditures per diluted share (TTM)
$0.03
R&D per diluted share (TTM)
$2.13
Stock compensation per diluted share (TTM)
$1.03
Book value per share
$-2.18

Growth

11 metrics
Revenue growth YoY
+199.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$188.73M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.5%
Year over year · more shares
Revenue CAGR (3Y)
+19.5%
Revenue CAGR (5Y)
+56.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-38.7%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
−$66.34M
Free cash flow (TTM)
−$159.13M
Quick ratio
3.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$90.70M
Latest balance sheet
Cash & equivalents
$79.13M
Total assets
$252.59M
Total debt
$200.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$158.92M
Capital expenditures (TTM)
$218,000
R&D (TTM)
$61.26M
SG&A (TTM)
$176.85M
Stock compensation (TTM)
$16.11M
R&D / revenue
32.5%
Stock compensation / revenue
8.5%

Ownership (13F)

9 metrics
13F filers
191
13F filer change QoQ
+16
Institutional ownership
87.6%
Conviction holders (share of 13F filers)
3.2%
Crowding (high-turnover and private-fund holders)
43.5%
Private-fund adviser ownership
34.3%
Active holders' share change QoQ
-12.7%
Holder tenure
11.4
Price vs estimated holder cost
+105.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.0%

Short interest

3 metrics
Short interest
11.5%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.04M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1668243 CUSIP M96088105 13F (30d) 24 filings 24 filers Visit website Investor relations